CAR-NK Cell Therapy Patents

CAR-NK cell therapy patents cover NK-cell-sourcing innovations; NK-optimized CAR-design innovations; persistence-enhancement innovations; and manufacturing, additional-engineering, and off-the-shelf innovations — with IP held by NK-cell-therapy companies and cancer-immunotherapy firms (in a field engineering natural killer (NK) cells with chimeric antigen receptors as an off-the-shelf, safer alternative to autologous CAR-T). WHY CAR-NK: CAR-T cells (engineered T cells) are powerful but must be made individually from each patient (autologous — slow, costly), can cause severe cytokine-release syndrome (CRS)/neurotoxicity, and cause graft-vs-host disease (GvHD) if from a donor; NATURAL KILLER (NK) cells engineered with a CAR offer key advantages — they do NOT cause GvHD, so they can be made OFF-THE-SHELF/allogeneic (from donors, cord blood, or iPSCs for many patients), they kill via BOTH the CAR and native NK receptors (potentially reducing antigen escape), and they cause less CRS/neurotoxicity (safer); the main drawback is NK cells' short persistence. MAJOR CAR-NK PATENT HOLDERS: FATE THERAPEUTICS: iPSC-derived (induced pluripotent stem cell) off-the-shelf CAR-NK (a renewable, engineered master-cell-line approach). NKARTA: engineered CAR-NK with persistence enhancements. CENTURY THERAPEUTICS (iPSC NK/T), MD ANDERSON/TAKEDA (cord-blood CAR-NK with IL-15), WUGEN, CATAMARAN BIO, INDAPTA, AFFIMED (innate-cell engagers). NK sourcing, NK-optimized CAR design, persistence, and manufacturing/engineering/off-the-shelf are the core CAR-NK patent domains — and iPSC sourcing, persistence (IL-15), NK-specific CARs, and off-the-shelf manufacturing are the open whitespace.

NK-cell-sourcing innovations; iPSC-derived-NK innovations; NK-optimized CAR-design innovations; and dual-killing and antigen-targeting innovations represent core CAR-NK patent domains — and where the NK cells come from and how the CAR is designed FOR NK biology (not just copied from T cells) are foundational, high-value choices. NK-CELL-SOURCING PATENTS: the source of NK cells — peripheral blood, CORD BLOOD (a common allogeneic source, MD Anderson/Takeda), the NK-92 cell line, and especially iPSC-DERIVED NK cells; the sourcing and isolation/selection methods strongly shape the product. iPSC-DERIVED-NK PATENTS: deriving NK cells from induced pluripotent stem cells — a renewable, clonal, master-cell-line source that can be extensively engineered ONCE and expanded indefinitely (Fate/Century); iPSC differentiation to NK and the engineered iPSC line are major, high-value IP (a defining off-the-shelf approach). NK-OPTIMIZED CAR-DESIGN PATENTS: NK cells signal differently from T cells, so CARs must be OPTIMIZED for NK — NK-specific signaling/costimulatory domains (e.g., NKG2D, 2B4, DAP10/DAP12 vs T-cell CD3ζ/CD28/4-1BB), hinge/transmembrane choices, and CAR architecture tuned for NK potency; NK-tailored CAR designs (vs reusing T-cell CARs) are core composition IP. DUAL-KILLING / ANTIGEN-TARGETING PATENTS: leveraging NK cells' NATIVE killing receptors alongside the CAR (so tumors can't escape by losing the CAR target), CD16/ADCC for antibody combination, and antigen targets (CD19, BCMA, solid-tumor antigens). iPSC-derived renewable NK sources, NK-optimized CAR designs (NK-specific signaling), and dual CAR-plus-native-receptor killing are the highest-value sourcing/design IP because the cell source and NK-tailored CAR determine manufacturability and potency.

Persistence-enhancement (IL-15) innovations; expansion and manufacturing innovations; additional-engineering (knockouts/armoring) innovations; and off-the-shelf, cryopreservation, and solid-tumor innovations represent additional CAR-NK patent domains — and extending NK cells' short lifespan and manufacturing them at off-the-shelf scale are the central challenges that define a viable CAR-NK product. PERSISTENCE-ENHANCEMENT / IL-15 PATENTS: NK cells persist for a short time in vivo (the key limitation vs CAR-T), so engineering PERSISTENCE — membrane-bound or secreted IL-15 (and IL-15/IL-15Rα fusions) that support NK survival/proliferation (MD Anderson/Takeda, Fate, Nkarta), and other cytokine support — is THE highest-value, make-or-break CAR-NK IP. EXPANSION / MANUFACTURING PATENTS: producing NK cells at therapeutic doses — feeder-cell or feeder-free expansion, iPSC differentiation/manufacturing, and consistent large-scale, multi-dose production (off-the-shelf needs many doses per batch); manufacturing is critical for the allogeneic value proposition. ADDITIONAL-ENGINEERING PATENTS: further engineering NK potency — KNOCKING OUT inhibitory checkpoints (e.g., CISH, a key NK brake), adding cytokines/armor against the tumor microenvironment, enhancing CD16/ADCC, and resisting NK fratricide; multiplex engineering (esp on iPSC lines) is high-value. OFF-THE-SHELF / CRYOPRESERVATION / SOLID-TUMOR PATENTS: cryopreservation and logistics for true off-the-shelf use (thaw-and-infuse), reducing/eliminating lymphodepletion, and extending CAR-NK to solid tumors (trafficking/persistence in the tumor microenvironment). Persistence engineering (IL-15), scalable off-the-shelf manufacturing, and potency-enhancing knockouts/armoring are the highest-value CAR-NK IP because persistence and manufacturing — not the CAR concept — determine whether CAR-NK delivers durable, scalable efficacy.

CAR-NK startup IP strategy must navigate Fate/Nkarta/Takeda-MD Anderson portfolios and broad CAR/cell-therapy prior art (CAR constructs, CAR-T, and NK biology have substantial IP — including foundational CAR patents and IL-15 IP), the PERSISTENCE challenge (the defining limitation), the manufacturing/iPSC and off-the-shelf-scale realities, the safety advantage and efficacy-durability trade-offs, the FTO around CARs/IL-15/iPSC, and a landscape where NK sourcing, NK-optimized CARs, persistence, and manufacturing are the durable assets; understand that CAR concepts and NK biology are well-trodden, so the durable IP is in iPSC-derived NK, NK-optimized CAR designs, IL-15/persistence engineering, multiplex knockouts, and off-the-shelf manufacturing, and that persistence, manufacturing scale, safety, and FTO matter as much as patents; identify whitespace in persistence, iPSC engineering, and NK-specific CARs. CAR-NK STARTUP IP STRATEGY: CAR CONCEPTS AND NK BIOLOGY ARE WELL-TRODDEN — SOURCING, NK-CARs, PERSISTENCE, AND MANUFACTURING ARE THE IP (AND FTO): foundational CAR and cell-therapy IP exists, so patent iPSC-NK, NK-optimized CARs, persistence engineering, and manufacturing — and clear FTO on CAR constructs, IL-15, and iPSC platforms; PERSISTENCE (IL-15 ARMORING) IS THE DEFINING LIMITATION AND HIGHEST-VALUE IP: NK cells are short-lived — membrane-bound IL-15 and persistence engineering are make-or-break and the most valuable, defensible CAR-NK IP (though IL-15 IP is contested — check FTO); iPSC-DERIVED NK IS A POWERFUL OFF-THE-SHELF PLATFORM: a renewable, multiplex-engineered clonal NK source (Fate/Century) enables scalable off-the-shelf therapy and is high-value platform IP; OFF-THE-SHELF/GvHD-FREE IS THE CORE ADVANTAGE OVER CAR-T: NK cells' lack of GvHD enables allogeneic, off-the-shelf products — protect manufacturing/logistics that realize this; NK-OPTIMIZED CARs DIFFERENTIATE FROM T-CELL CARs: NK-specific signaling/costimulation (NKG2D/DAP10/DAP12) tuned for NK potency is defensible composition IP; MULTIPLEX ENGINEERING (CISH KNOCKOUT, ARMORING) BOOSTS POTENCY: removing NK brakes and arming against the tumor microenvironment (easiest on iPSC lines) is high-value; SAFETY (LOWER CRS) IS A KEY POSITIONING ADVANTAGE: emphasize and protect the safety profile vs CAR-T; SOLID TUMORS AND DURABILITY ARE THE FRONTIER: extending CAR-NK efficacy/persistence to solid tumors is the next high-value challenge; WHEN TO PATENT: NOVEL SOURCE/CAR/PERSISTENCE/PROCESS WITH MEASURED OUTCOMES: file once a construct/cell/process shows measured results (persistence/expansion + cytotoxicity/potency + response rate + safety (CRS/neurotox) + manufacturing yield/doses-per-batch + off-the-shelf logistics) vs. CAR-T/unmodified-NK baselines — measured persistence, potency, safety, and manufacturing scale are the critical CAR-NK IP metrics; KEY FTO CHECKLIST: Fate iPSC-derived off-the-shelf CAR-NK; Nkarta persistence-enhanced CAR-NK; Takeda/MD Anderson cord-blood CAR-NK + IL-15; Century iPSC; NK sourcing cord-blood/peripheral/NK-92/iPSC; iPSC NK differentiation + engineered master line; NK-optimized CAR signaling (NKG2D/2B4/DAP10/DAP12 vs CD3ζ/CD28/4-1BB); dual CAR + native-receptor killing/CD16-ADCC; membrane-bound/secreted IL-15 persistence (FTO); feeder/feeder-free expansion + off-the-shelf multi-dose manufacturing; CISH/checkpoint knockout/armoring/fratricide; cryopreservation/lymphodepletion-sparing; solid-tumor trafficking; foundational CAR + CAR-T + IL-15 + iPSC prior art/FTO.